Sandbox vidit5: Difference between revisions
Jump to navigation
Jump to search
Line 19: | Line 19: | ||
{{familytree | | | | | | | | D01 | | | | | |D01=<div style="float: left; text-align: left">Do all 3 simultaneously <br> ❑ Call for help <br> ❑'''Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution''' <br>Maximum dose 0.5 mg (adult) or 0.3 mg (child) <br> Record the time of the dose and repeat it in 5-10 minutes, if needed or <br> ❑ In patients with hypotension/cardiorespiratory arrest and those not responding: Intravenous epinephrine <br> 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) <br> Titrate based on clinical response or epinephrine side effects <br> ❑ Place patient on back/comfortable position; elevate legs</div> }} | {{familytree | | | | | | | | D01 | | | | | |D01=<div style="float: left; text-align: left">Do all 3 simultaneously <br> ❑ Call for help <br> ❑'''Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution''' <br>Maximum dose 0.5 mg (adult) or 0.3 mg (child) <br> Record the time of the dose and repeat it in 5-10 minutes, if needed or <br> ❑ In patients with hypotension/cardiorespiratory arrest and those not responding: Intravenous epinephrine <br> 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) <br> Titrate based on clinical response or epinephrine side effects <br> ❑ Place patient on back/comfortable position; elevate legs</div> }} | ||
{{familytree | | | | | | | | |!| | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | }} | ||
{{familytree | | | | E02 |-| E01 | | | | | | | |E01= Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease |E02=Yes}} | {{familytree | | | | E02 |-| E01 | | | | | | | |E01=<div style="float: left; text-align: left"> Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease </div> |E02=Yes}} | ||
{{familytree | | | | |!| | | |!| | | | | | | | }} | {{familytree | | | | |!| | | |!| | | | | | | | }} | ||
{{familytree | | | | F01 | | F02 | | | | | | |F01= ❑ Give high flow supplemental oxygen (6-8 L/min) |F02=No }} | {{familytree | | | | F01 | | F02 | | | | | | |F01= ❑ Give high flow supplemental oxygen (6-8 L/min) |F02=No }} | ||
Line 25: | Line 25: | ||
{{familytree | | | | |`|-|-| G01 |-| G02 | | | |G01=Patient hypotensive despite epinephrine? |G02=Yes }} | {{familytree | | | | |`|-|-| G01 |-| G02 | | | |G01=Patient hypotensive despite epinephrine? |G02=Yes }} | ||
{{familytree | | | | | | | | |!| | | |!| | | | }} | {{familytree | | | | | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<left> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </ | {{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<div style="float: left; text-align: left"> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </div> }} | ||
{{familytree | | | | | | | | |!| | | |!| | | | }} | {{familytree | | | | | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | | | | | I01 |-|-|'| | | |I01=Secondary therapy after epinephrine (evidence not clear) <br> H1 antihistaminics: <br> Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children | {{familytree | | | | | | | | I01 |-|-|'| | | |I01=<div style="float: left; text-align: left"> Secondary therapy after epinephrine (evidence not clear) <br> H1 antihistaminics: <br> ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children | ||
---- | ---- | ||
H2 antihistaminics: <br> Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM }} | H2 antihistaminics: <br> ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM </div>}} | ||
{{familytree | | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | | J01 | | | | | | |J01=Observe the patient for biphasic anaphylaxis <br> Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br> Provide auto-injectable epinephrine and action plan for future events at discharge }} | {{familytree | | | | | | | | J01 | | | | | | |J01=<div style="float: left; text-align: left"> ❑ Observe the patient for biphasic anaphylaxis <br> | ||
: Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br> ❑ Provide auto-injectable epinephrine and action plan for future events at discharge </div> }} | |||
{{familytree/end}} | {{familytree/end}} |
Revision as of 14:22, 17 January 2014
Management
Shown below is an algorithm summarizing the approach to [[disease name]].
Characterize the symptoms & signs: Skin, subcutaneous tissue and mucosa: ❑ Flushing, itching, urticaria, angioedema, rash, piloerection ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing Respiratory: Gastrointenstinal: Cardiovascular: Central nervous system: ❑ Anxiety, irritability ❑ Throbbing headache ❑ Altered vision and mental status | |||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Acute asthma ❑ Anxiety/Panic attack ❑ Syncope | |||||||||||||||||||||||||||||||||
Remove patient from exposure/trigger | |||||||||||||||||||||||||||||||||
Do all 3 simultaneously ❑ Call for help ❑Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution Maximum dose 0.5 mg (adult) or 0.3 mg (child) Record the time of the dose and repeat it in 5-10 minutes, if needed or ❑ In patients with hypotension/cardiorespiratory arrest and those not responding: Intravenous epinephrine 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) Titrate based on clinical response or epinephrine side effects ❑ Place patient on back/comfortable position; elevate legs | |||||||||||||||||||||||||||||||||
Yes | Patient has one of the following? ❑ Respiratory distress ❑ Recieved repeated doses of epinephrine ❑ Asthma/other respiratory disease ❑ Co-existing cardiovascular disease | ||||||||||||||||||||||||||||||||
❑ Give high flow supplemental oxygen (6-8 L/min) | No | ||||||||||||||||||||||||||||||||
Patient hypotensive despite epinephrine? | Yes | ||||||||||||||||||||||||||||||||
No | ❑ Establish IV access ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg | ||||||||||||||||||||||||||||||||
Secondary therapy after epinephrine (evidence not clear) H1 antihistaminics: ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children H2 antihistaminics: ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM | |||||||||||||||||||||||||||||||||
❑ Observe the patient for biphasic anaphylaxis
| |||||||||||||||||||||||||||||||||